Removal of two cytostatic drugs: bleomycin and vincristine by white-rot fungi - a sorption study.

J Environ Health Sci Eng

Environmental Biotechnology Department, Faculty of Energy and Environmental Engineering, The Silesian University of Technology, Akademicka 2, 44-100 Gliwice, Poland.

Published: June 2021

Purpose: Cytostatic drugs cannot be easily removed by conventional sewage treatment plants, resulting in their ultimate release into aquatic systems where they become a threat. Thus, new technologies which can be used to eliminate these drugs more effectively before they enter the environment are increasingly important. Fungal treatment of wastewaters is a promising and environmentally friendly technology for pharmaceutical remediation. The aim of this work is to examine the biosorption of two cytostatics, bleomycin and vincristine, in the aqueous solution by fungal biomass.

Methods: Five white-rot fungi were used in this study: (CB13), (CB15), (CB14), (BWPH), and (CB8). Tests were conducted on different types of biomass (alive and dead - autoclaved) and in various physico-chemical conditions: varied drug concentrations (5, 10 and 15 mg/L), temperatures (from 15.4 to 29.6 °C), and pH (from 3.2 to 8.8).

Results: The results showed that among alive biomass, (CB8) had the greatest sorption ability for bleomycin and (CB14) worked best for vincristine. The tested sorption process could be described by a pseudo-second order kinetics model. Sorption equilibrium studies demonstrated that for bleomycin Redlich-Peterson, while for vincristine Langmuir model fitted best. The thermodynamic studies showed that the sorption process was endothermic chemisorption for bleomycin, and exothermic physisorption for vincristine. For both drugs the sorption ability increased with an increase of the pH value.

Conclusion: The biosorption on fungal biomass is a favorable alternative to conventional wastewater treatment processes for anticancer drug removal.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172822PMC
http://dx.doi.org/10.1007/s40201-021-00635-8DOI Listing

Publication Analysis

Top Keywords

cytostatic drugs
8
bleomycin vincristine
8
white-rot fungi
8
sorption ability
8
sorption process
8
sorption
6
bleomycin
5
vincristine
5
removal cytostatic
4
drugs
4

Similar Publications

Molecular Pharmacology of Dasatinib Provides Unique Insights into the Mechanistic Basis of Success and Failure of Targeted Cancer Therapy.

ACS Pharmacol Transl Sci

January 2025

Department of Cell and Molecular Biology, University of Rhode Island, 120 Flagg Rd, Kingston, Rhode Island 02881, United States.

Despite the enthusiasm for targeted cancer therapies in preclinical studies and the success of a select few drugs, many promising drug candidates fail in clinical trials. The gap between preclinical promise and clinical outcomes underscores the need to investigate factors influencing the success or failure of targeted therapies. Dasatinib, an inhibitor of Abl and Src protein tyrosine kinases, is highly effective toward chronic myeloid leukemia (CML) by targeting BCR-Abl, but it is ineffective against solid tumors when targeting Src kinases.

View Article and Find Full Text PDF

Hepatocellular carcinoma () is one of the leading causes of cancer deaths due to its late diagnosis and restricted therapeutic options. Therefore, the search for appropriate alternatives to commonly applied therapies remains an area of high clinical need. Here we investigated the therapeutic potential of the glucosylceramide synthase (GCS) inhibitor Genz-123346 and the cationic amphiphilic drug aripiprazole on the inhibition of Huh7 and Hepa 1-6 hepatocellular cancer cell and tumor microsphere growth.

View Article and Find Full Text PDF

Background/objectives: Glioblastoma (GBM) is the most aggressive type of brain tumor in adults. Currently, the only treatments available are surgery, radiotherapy, and chemotherapy based on temozolomide (TMZ); however, the prognosis is dismal. Several natural substances are under investigation for cancer treatment.

View Article and Find Full Text PDF

Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies.

Cancers (Basel)

December 2024

Division of Histology and Embryology, Department of Human Morphology and Embryology, Faculty of Medicine, Wroclaw Medical University, 50-368 Wroclaw, Poland.

Despite the great advancements in treatment strategies for hematological malignancies (HMs) over the years, their effective treatment remains challenging. Conventional treatment strategies are burdened with several serious drawbacks limiting their effectiveness and safety. Improved understanding of tumor immunobiology has provided novel anti-cancer strategies targeting selected immune response components.

View Article and Find Full Text PDF

Novel thermosensitive small multilamellar lipid nanoparticles with promising release characteristics made by dual centrifugation.

Eur J Pharm Sci

December 2024

Institute of Pharmaceutical Sciences, University of Freiburg, 79104 Freiburg im Breisgau, Germany; Andreas Hettich GmbH, 78532 Tuttlingen, Germany. Electronic address:

Thermosensitive liposomes (TSLs) have great potential for the selective delivery of cytostatic drugs to the tumor site with greatly reduced side effects. Here we report the discovery and characterization of new thermosensitive small multilamellar lipid nanoparticles (tSMLPs) with unusually high temperature selectivity. Furthermore, the temperature-dependent release of the fluorescent marker calcein from tSMLPs is enhanced by human serum albumin.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!